Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 6/20 | 0.45 |
| ▸ | RXRB | P28702 | 6/20 | 0.45 |
| ▸ | RXRG | P48443 | 5/20 | 0.45 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | KIF11 | P52732 | 2/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGAV | P06756 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13866628 | 0.90 | RXRA (0.52) | RXRARXRBRXRGIDO1KIF11 | |
| SCHEMBL9482063 | 0.87 | RXRA (0.54) | RXRARXRBRXRGIDO1KIF11 | |
| SCHEMBL28673629 | 0.85 | RXRA (0.48) | RXRARXRBRXRGIDO1KIF11 | |
| SCHEMBL23045013 | 0.84 | KIF11 (0.44) | RXRARXRBRXRGIDO1KIF11 | |
| SCHEMBL9315932 | 0.84 | TSHR (0.48) | RXRARXRBRXRGIDO1KIF11 | |
| Boric Acid SCHEMBL27957819 | 0.82 | RXRA (0.47) | RXRARXRBRXRGKIF11CES2 | |
| SCHEMBL1227529 | 0.82 | RXRA (0.47) | RXRARXRBRXRGIDO1KIF11 | |
| SCHEMBL29576147 | 0.80 | TSHR (0.50) | RXRARXRBRXRGIDO1KIF11 | |
| SCHEMBL716180 | 0.80 | TSHR (0.50) | RXRARXRBRXRGIDO1KIF11 | |
| SCHEMBL24038121 | 0.78 | RXRA (0.44) | RXRARXRBRXRGIDO1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242278-B2 | Process for producing biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-14 | — | — | US | disclosed |
| US-20120101278-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | HAGIYA KOJI (JP) | 2012-04-26 | — | — | US | disclosed |
| EP-1473286-B1 | PROCESS FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2009-11-04 | — | — | EP | disclosed |
| US-20090216017-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | HAGIYA KOJI | 2009-08-27 | — | — | US | disclosed |
| US-7554000-B2 | Process for producing biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-06-30 | — | — | US | disclosed |
| US-20050096471-A1 | Process for producing biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-05-05 | — | — | US | disclosed |
| EP-1473286-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2004-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101278-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | PPOX, CAT, TYR | RXRA 1657/4885RXRB 2002/4885RXRG 2446/4885 |
| US-20090216017-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | PPOX, CAT, TYR | RXRA 1657/4885RXRB 2002/4885RXRG 2446/4885 |
| US-20050096471-A1 | Process for producing biaryl compound | PPOX, CAT, TYR | RXRA 1657/4885RXRB 2002/4885RXRG 2446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.